CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages

CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price